ArticleNeurosurgical review2025
Robot-assisted stereotactic minimally invasive aspiration and irrigation (RASMIAI): a novel approach for severe intraventricular hemorrhage.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Severe intraventricular hemorrhage (SIVH; Graeb score ≥ 9) presents significant therapeutic challenges, including delayed hematoma resolution, CSF pathway obstruction, brainstem compression from fourth ventricular dilation, and infection risks associated with prolonged catheterization. This study evaluates the efficacy and safety of robot-assisted stereotactic minimally invasive aspiration and irrigation (RASMIAI) without fibrinolytic therapy as an alternative to conventional interventions. A retrospective analysis of 35 consecutive SIVH patients treated between January 2024 and January 2025 compared outcomes between RASMIAI group (n = 16) and conventional therapies (n = 19: stereotactic surgery, endoscopic evacuation, or external ventricular drainage [EVD]), as the control group. Procedural metrics, hematoma clearance, CSF circulation restoration, complications, mortality, and 90-day functional outcomes (mRS, GOS) were analyzed. Baseline demographics, Graeb scores, and Glasgow Coma Scale (GCS) scores were comparable between groups (p > 0.05). RASMIAI demonstrated superior procedural efficiency (47.2 ± 8.2 vs. 90.8 ± 51.4 min, p = 0.002), with significantly higher 24-hour hematoma clearance (85.6 ± 9.6% vs. 38.4 ± 20.9%, p < 0.001) and faster CSF pathway restoration (1.3 ± 0.48 vs. 7.9 ± 2.4 days, p < 0.001). Postoperative imaging revealed near-complete hematoma resolution (Graeb score: 1.5 ± 0.97 vs. 6.1 ± 2.0, p < 0.001). The RASMIAI cohort exhibited no intracranial infections (0% vs. 31.6%, p = 0.014) and zero mortality at 90 days (0% vs. 36.8%, p = 0.007). Functional outcomes favored RASMIAI, with significantly improved the modified Rankin Scale (mRS) and Glasgow Outcome Scale (GOS) scores (p < 0.01). RASMIAI represents a paradigm shift in SIVH management, enabling simultaneous supratentorial and fourth ventricular hematoma evacuation without fibrinolytic agents. Its precision-driven approach reduces procedural time, enhances hematoma clearance, accelerates neurological recovery, and mitigates infection and mortality risks. These findings may indicate RASMIAI as a promising minimally invasive technique for severe IVH cases.
Indexed as
Identifiers
41165880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.